Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H14N2O6S3.2Na |
Molecular Weight | 448.445 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[O-]S(=O)CNC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NCS([O-])=O)C=C2
InChI
InChIKey=AZBNFLZFSZDPQF-UHFFFAOYSA-L
InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H14N2O6S3 |
Molecular Weight | 402.466 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sulfoxone is a water-soluble sulfone and is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Sulfoxone under the brand name Diasone was used as an antileprosy drug, for treatment of dermatitis herpetiformis, and to treat pulmonary tuberculosis. Presently, usage of diasone has been discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362993 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6753759 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DIASONE SODIUM Approved UseUnknown Launch Date5.11401591E11 |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14888329 |
Primary | DIASONE SODIUM Approved UseUnknown Launch Date5.11401591E11 |
||
Primary | DIASONE SODIUM Approved UseUnknown Launch Date5.11401591E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
2.4 g single, oral Studied dose |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
Other AEs: Nausea, Weakness... |
2.4 g single, oral Studied dose |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
Other AEs: Malaise... |
1.2 g 1 times / day multiple, oral Dose: 1.2 g, 1 times / day Route: oral Route: multiple Dose: 1.2 g, 1 times / day Sources: |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
Disc. AE: Hemolytic anemia, Methemoglobinemia... AEs leading to discontinuation/dose reduction: Hemolytic anemia Sources: Methemoglobinemia |
0.3 g 3 times / day multiple, oral Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 52 years n = 1 Health Status: unhealthy Condition: leprosy Age Group: 52 years Sex: M Population Size: 1 Sources: |
Disc. AE: Erythema facial, Erythema... AEs leading to discontinuation/dose reduction: Erythema facial Sources: Erythema Furunculosis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 2.4 g single, oral Studied dose |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
|
Weakness | 2.4 g single, oral Studied dose |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
|
Malaise | 2.4 g single, oral Studied dose |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
|
Hemolytic anemia | Disc. AE | 1.2 g 1 times / day multiple, oral Dose: 1.2 g, 1 times / day Route: oral Route: multiple Dose: 1.2 g, 1 times / day Sources: |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
Methemoglobinemia | Disc. AE | 1.2 g 1 times / day multiple, oral Dose: 1.2 g, 1 times / day Route: oral Route: multiple Dose: 1.2 g, 1 times / day Sources: |
unhealthy, 50 years Health Status: unhealthy Condition: leprosy Age Group: 50 years Sex: M Sources: |
Erythema facial | Disc. AE | 0.3 g 3 times / day multiple, oral Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 52 years n = 1 Health Status: unhealthy Condition: leprosy Age Group: 52 years Sex: M Population Size: 1 Sources: |
Erythema | Disc. AE | 0.3 g 3 times / day multiple, oral Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 52 years n = 1 Health Status: unhealthy Condition: leprosy Age Group: 52 years Sex: M Population Size: 1 Sources: |
Furunculosis | Disc. AE | 0.3 g 3 times / day multiple, oral Dose: 0.3 g, 3 times / day Route: oral Route: multiple Dose: 0.3 g, 3 times / day Sources: |
unhealthy, 52 years n = 1 Health Status: unhealthy Condition: leprosy Age Group: 52 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
p-Sulfooxyphenylpyruvic acid from the red macro alga Ceratodictyon spongiosum and its sponge symbiont Haliclona cymaeformis. | 2002 Jun |
|
Asymmetric synthesis of anti-homopropargylic alcohols from aldehydes and chiral sulfonimidoyl substituted bis(allyl)titanium complexes through generation and elimination of novel chiral alkylidenecarbene (dimethylamino)sulfoxonium ylides. | 2002 Sep 4 |
|
Asymmetric synthesis of unsaturated, fused bicyclic proline analogues through amino alkylation of cyclic bis(allylsulfoximine)titanium complexes and migratory cyclization of delta-amino alkenyl aminosulfoxonium salts. | 2003 Oct 29 |
|
Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS). | 2005 |
|
Avoid, attack or do both? Behavioral and physiological adaptations in natural enemies faced with novel hosts. | 2005 Nov 4 |
|
Diastereomerically and enantiomerically pure 2,3-disubstituted pyrrolidines from 2,3-aziridin-1-ols using a sulfoxonium ylide: a one-carbon homologative relay ring expansion. | 2007 Feb 21 |
|
Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. | 2007 Mar 15 |
|
Beneficial effects of a diabetes specific formula on insulin sensitivity and free fatty acid in patients with type 2 diabetes mellitus. | 2008 Apr 20 |
|
Impact of glycemic control on the incidence of acute kidney injury in critically ill patients: a comparison of two strategies using the RIFLE criteria. | 2010 Jun |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:53 UTC 2023
by
admin
on
Fri Dec 15 15:01:53 UTC 2023
|
Record UNII |
57OWB0Q221
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29739
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
||
|
WHO-ATC |
J04BA03
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ALDESULFONE SODIUM
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
DB01145
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
m10368
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000087868
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
27222
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
SUB05304MIG
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL1570
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
8954
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
971
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
C036115
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
144-75-2
Created by
admin on Fri Dec 15 15:01:53 UTC 2023 , Edited by admin on Fri Dec 15 15:01:53 UTC 2023
|
PRIMARY | |||
|
C66574
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
DTXSID9023623
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY | |||
|
57OWB0Q221
Created by
admin on Fri Dec 15 15:01:54 UTC 2023 , Edited by admin on Fri Dec 15 15:01:54 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |